• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconGLP-1s

GLP-1s

Page 2 of 3
The ‘quiet alarm bell’ on U.S. health costs: Employers are backed into a corner, and workers are paying the price
Economy
The ‘quiet alarm bell’ on U.S. health costs: Employers are backed into a corner, and workers are paying the price
By Ashley LutzOctober 22, 2025
Ozempic
Commentary
Trump wants Medicare to pay for your Ozempic treatment. Taxpayers may foot the bill for billions in fraud
By Ari Yampolsky and Max VoldmanAugust 12, 2025
Exclusive: The founders of SoulCycle built a startup for relationships, then pivoted to GLP-1 support groups. Now its assets are being acquired by WeightWatchers
Newsletters
Exclusive: The founders of SoulCycle built a startup for relationships, then pivoted to GLP-1 support groups. Now its assets are being acquired by WeightWatchers
By Emma HinchliffeAugust 7, 2025
OpenAI CEO Sam Altman testifies during a Senate Commerce, Science and Transportation Committee hearing on May 8, 2025. (Photo: Tom Williams/CQ-Roll Call/Getty Images)
Newsletters
Behold, an AI model from OpenAI that’s…open
By Andrew NuscaAugust 6, 2025
Weight-loss drugs should be first step to prevent heart disease, top cardiology group says
Health
Weight-loss drugs should be first step to prevent heart disease, top cardiology group says
By Michelle Amponsah and BloombergJune 20, 2025
Closeup of woman's torso in orange sweater holding injectable weight-loss drug.
Lifestyle
Agency warns that weight-loss drugs can decrease effectiveness of birth control pills
By Beth GreenfieldJune 5, 2025
A group of young women sit around a table at a restaurant.
Health
The Ozempic boom could be bad news for restaurants as more than half of GLP-1 users report cutting back on dining out, report finds
By Sasha RogelbergJune 4, 2025
Interest in GLP-1 medications like Ozempic will continue to grow given the multiple health conditions they can improve.
Commentary
The crisis over GLP-1 out-of-pocket costs deepens—it’s time for health-care leaders to step up
By Wendy BarnesMarch 4, 2025
Close up of a man's face
Health
50-year-old security guard lost 70 pounds on Wegovy—then gained two pants sizes when he lost insurance coverage
By Tom Murphy and The Associated PressFebruary 24, 2025
Semaglutide medications Wegovy and Ozempic are pictured
Health
Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers
By Bloomberg, Madison Muller, Ike Swetlitz and Naomi KresgeFebruary 21, 2025
A woman injects herself with medication.
Health
Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’
By Lindsey LeakeFebruary 11, 2025
Close-up of cast metal sign for the pharmaceutical company Merck
Health
Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential
By Hallie SteinerFebruary 4, 2025
Novo Nordisk advertising logo on facade building, Danish pharmaceutical healthcare giant Novo Nordisk AS, production innovative drugs, obesity treatment Ozempic, Mainz, Germany June 15, 2024
Health
Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
By Ryan HoggFebruary 4, 2025
A person stands on a scale.
Health
Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs
By Lindsey LeakeFebruary 3, 2025
Ozempic and Wegovy medications side by side
Health
Ozempic and Wegovy surge to national approval with most U.S. adults considering it ‘a good thing’ to treat obesity
By The Associated Press, Kenya Hunter and Linley SandersJanuary 31, 2025
1
  • 1
  • 2
  • 3
3
Most Popular
Big Tech
Jensen Huang made his $172 billion fortune on AI chips. His family's $75 million gift to Vanderbilt argues art decides what technology is forplaceholder alt text
By Sydney LakeJuly 23, 2026
Economy
'The demographic dividend of the last 40 years is ending': J.P. Morgan says the world is running out of the two things that kept interest rates downplaceholder alt text
By Eleanor PringleJuly 24, 2026
Economy
The $39 trillion U.S. national debt isn’t as high as Japan’s and Singapore’s relative to economy size—and yet it's still worse somehowplaceholder alt text
By Sasha RogelbergJuly 23, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.